Aimed at achieving a paradigm shift in Oncology research by imaging and quantifying fluorescent signals deep in the brain of animal models and to quantitate the molecular response of biomarkers to therapy
February 3, 2020¶ – Nicosia, Cyprus and Utrecht, the Netherlands
EPOS-Iasis Research and Development Ltd and the University of Cyprus UCY have acquired a MILabs Hybrid Optical/CT system as a key component of their recently established state-of-the-art Biotechnology and Nanobiotechnology Laboratory. In the context of the HORIZON 2020, European Innovation Council Program, EPOS-Iasis has been tasked with undertaking the scientific coordination of GLADIATOR FETOpen, a Future Emerging Technologies program for the application of next-generation theranostics (therapeutic and diagnostic) platforms for the management of brain pathologies, epitomized by glioblastoma, the most deathly human tumor.
These platforms will be comprised of optically active bio-nanomachines organized in nanonetworks and functioning under the control of external bio-nanodevice interfaces. MILabs cutting-edge in-vivo optical/CT system will be used for disruptive research on the spatiotemporal interaction of tumor-released fluorescent vesicles known as exosomes and genetically engineered cells which are converted to optical switches, thus providing continuous and real time monitoring of disease evolution, progression and response to therapy.
According to Andreani D. Odysseos, MD/PhD, a founding member of EPOS-Iasis and Head of Translational Nanomedicine and Nanobiotechnology, “MILabs Optical/CT system offers the ability to achieve a paradigm shift in Oncology research by imaging and quantifying fluorescent signals deep in the brain of animal models and to quantitate the molecular response of biomarkers to therapy derived from genetically engineered organoids while enabling visualization and quantification of the interaction between brain tumor vesicles and optical molecular switches. This will enable us to deliver a multifunctional and multimodal brain tumor reprogramming and monitoring platform based on autonomous, externally controllable molecular communication (ECMC) technology for the management of malignant brain tumors, laying the foundation of expanding Europe’s technological future in multimodal molecular imaging “
Prof. Frederik Beekman states: “We are looking forward to support EPOS-Iasis with our CT-guided optical imaging technology so that it can establish itself as a leading molecular optical imaging and nanotheranostics enterprise”
About EPOS-Iasis Research and Development, Ltd.
The company is engaged in cutting-edge research in the field of molecular diagnostics and therapeutics. EPOS-Iasis actively collaborates with a wide network of local and international partners including the University of Cyprus and other leading Biomedical Research Institutes in EU, UK, Australia, US, Canada and Japan. These collaborations enhance and compliment the company’s primary long-term business objective to conduct research in the area of molecular medicine for the purpose of developing novel diagnostic and pharmaceutical products. For more information: https://www.epos-iasis.com/index.html
About MILabs B.V.
This fast-growing Dutch company has a history of providing a continuum of innovations to expand the applications preclinical molecular imaging. With its latest adaptive platform, MILabs has succeeded at commercializing a scalable imaging platform, able to accommodate Optical and CT imaging as well as the nuclear PET and SPECT techniques. MILabs has built a strong brand based on its mission of “Making Molecular Imaging Clear”. With ultra-high-resolution and multiparametric imaging complemented by theranostic capabilities, it provides efficient translational systems for both diagnostic and therapy applications. For more information, visit: www.milabs.com or contact MILabs at [email protected].
